The cannabis industry has swiftly turned into a multi-billion dollar opportunity. In the United States, this market’s massive growth potential is being recognized as new states legalize marijuana for medical or recreational use. Industry experts forecast the U.S. cannabis market rounding $7 billion in 2016, while the annual sale of state-legal cannabis products is forecast to exceed $20 billion by 2020. Within this flourishing market, cannabis-pharma companies like India Globalization Capital (NYSE: IGC) (IGC Profile), Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), OWC Pharmaceutical Research Corp. (OTC:OWCP), Insys Therapeutics, Inc. (NASDAQ: INSY) and GW Pharmaceuticals plc (NASDAQ: GWPH) are carving lanes of unprecedented opportunities in the medical field.
Bethesda, Maryland-based India Globalization Capital (NYSE: IGC)